scholarly journals Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study

2018 ◽  
Vol 9 (4) ◽  
pp. 1549-1567 ◽  
Author(s):  
Hisamitsu Ishihara ◽  
Susumu Yamaguchi ◽  
Ikko Nakao ◽  
Taishi Sakatani
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Japanese Patients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study

2014 ◽  
Vol 5 (2) ◽  
pp. 415-433 ◽  
Author(s):  
Kohei Kaku ◽  
Hiroshi Maegawa ◽  
Yukio Tanizawa ◽  
Arihiro Kiyosue ◽  
Yumiko Ide ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Japanese Patients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study

2017 ◽  
Vol 19 (11) ◽  
pp. 1625-1629 ◽  
Author(s):  
Juris J. Meier ◽  
Nina Schenker ◽  
Melanie Kahle ◽  
Freimut Schliess ◽  
Christoph Kapitza ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cell Function ◽  
Β Cell ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Β Cell Function

scholarly journals A Multicenter, Prospective, Observational, Open-Label Study of the Safety and Comfort of Gensulin® Delivery Device Use in a Large Cohort of Adult and Elderly Patients with Type 2 Diabetes

2020 ◽  
Vol 17 (20) ◽  
pp. 7587
Author(s):  
Małgorzata Masierek ◽  
Katarzyna Nabrdalik ◽  
Hanna Kwiendacz ◽  
Tomasz Sawczyn ◽  
Janusz Gumprecht
Keyword(s):  
Type 2 Diabetes ◽  
Elderly Patients ◽  
Real Life ◽  
Observation Data ◽  
Delivery Device ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Large Patient

Insulin treatment is necessary for many patients with type 2 diabetes, and its delivery must be safe and comfortable. This study evaluated patients’ safety and comfort when using a Gensulin® delivery device, GensuPen (Bioton), a reusable insulin pen device for injecting Gensulin® insulin among adult and elderly patients with type 2 diabetes. This was a 4-week multicenter, prospective, observational, open-label study in patients with diabetes mellitus type 2 who have recently started using a GensuPen. Overall, 10,309 patients (mean age: 63 ± 12.0 years; 47.9% female) were analyzed in this study. Of these, 2.5% had used an insulin delivery device before, and for 97.5%, GensuPen was the first delivery device they had used. Most (87.8%) of the patients rated the GensuPen as very good in setting the dose, 92.0% in confirmation of successful insulin administration, 80.9% in trigger location, and 75.0% in force needed for injection. The overall safety of the GensuPen use was high since severe hypoglycemia occurred only in 0.2% of the studied patients. There were 0.6% adverse events, none of which were serious. This real-life observation data shows that the GensuPen was well accepted and safe in this large patient population of adult and elderly patients with type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document